[CAS NO. 16290-26-9] 3,4-Dihydroxybenzylamine hydrobromide
PRODUCTS SPECIFICATIONS [16290-26-9]
DESCRIPTION [16290-26-9]
Overview
| MDL | MFCD00012859 |
|---|---|
| Molecular Weight | 220.06 |
| Molecular Formula | C7H10BrNO2 |
| SMILES | [H]Br.NCC1=CC(O)=C(O)C=C1 |
Summary
3,4-Dihydroxybenzylamine hydrobromide (NSC 263475 hydrobromide) is an improved dopamine analog cytotoxic and inhibits DNA polymerase activity in melanoma cells [2] . 3,4-Dihydroxybenzylamine hydrobromide (NSC 263475 hydrobromide) displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity [2] .
In Vitro
3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of all melanoma cell lines with an IC
50
of 100 μM, while the SK-MELB cell line exhibits an IC
50
of 122 μM. The IC
50
values are 30, 84,90, and 68 μM for Human SK-MEL-30, SK-MEL-2, SK-MEL-3,RPMI-7951 cells, respectively. It exhibits IC
50
values of 10, 25, 67, and 184 μM for S91A,S91B, L1210, and SCC-25 cells, respectively
[2]
.
3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) cytotoxicity in SK-MEL-2 and SK-MEL-28 cell lines can be enhanced by application of buthionine sulfoximine (BSO). BSO treatment sensitizes marginally pigmented cells to the effects of 3,4-DHBA, and the presence of decreses IC
50
values of 3,4-DHBA by 127% in the SK-MEL-28 cell line and by 148% in the SK-MEL-2 cell line
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines |
| Concentration: | 1 μM-10 mM |
| Incubation Time: | 48 hours |
| Result: | Inhibited melanoma cell Lines growth. |
In Vivo
3,4-Dihydroxybenzylamine hydrobromide (intraperitoneal injection; 1000 mg/kg; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose
[3]
.
3,4-Dihydroxybenzylamine hydrobromide (intraperitoneal injection; 200-800 mg/kg; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days for 0 mg/kg, 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, respectively
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6 mice with B6D2F1 cells [3] |
| Dosage: | 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Exhibited increased life-span of 44%,46%, 70% and 50% for 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, respectively. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 83.33 mg/mL ( 378.67 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.5442 mL | 22.7211 mL | 45.4422 mL |
| 5 mM | 0.9088 mL | 4.5442 mL | 9.0884 mL |
| 10 mM | 0.4544 mL | 2.2721 mL | 4.5442 mL |
References
- [1] FitzGerald GB, et al. 3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymerase.J Invest Dermatol. 1983 Feb;80(2):119-23.
- [2] Prezioso JA1,et al.Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.Pigment Cell Res. 1990 Mar-Apr;3(2):49-54.
- [3] Mlchael M. Wick,et al. 3,4-Dihydroxybenzylamine: Antitumor Activity Against A Dopamine Analog B16 Melanoma.
Synonyms